Impact of Choroidal Melanoma Characteristics on Progression-Free Survival in Patients Undergoing Hypofractionated Stereotactic Photon Radiotherapy.
Choroidal melanoma
Monitoring
Tumor characteristics
Ultrasonography
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
14
06
2023
accepted:
01
08
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
ppublish
Résumé
In an effort to replace ultrasonography-based thickness measurements, we investigated whether choroidal melanoma characteristics are related to progression-free survival (PFS) in patients monitored after linear accelerator (LINAC)-based hypofractionated stereotactic photon radiotherapy. In a retrospective dataset, we used a linear mixed model to assess the associations between PFS and tumor characteristics; in particular, thickness, largest basal diameter (LBD), base area and volume. Thickness and LBD are statistically significantly associated with PFS. In a subgroup of 16 patients undergoing enucleation due to melanoma recurrence or progression, there were statistically significant changes in mean thickness and LBD before surgery. Mean PFS was 42 ± 30 months. Ultrasonography-based thickness measurements may not be necessary for treated choroidal melanoma monitoring; instead, we propose sequential LBD assessments, which should preferably be performed using fundus photography in future.
Identifiants
pubmed: 37665498
doi: 10.1007/s40123-023-00790-1
pii: 10.1007/s40123-023-00790-1
pmc: PMC10640552
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3039-3046Informations de copyright
© 2023. The Author(s).
Références
Acta Ophthalmol (Copenh). 1982 Apr;60(2):161-82
pubmed: 7136531
Curr Eye Res. 2017 Aug;42(8):1085-1093
pubmed: 28494168
Arch Ophthalmol. 2005 Dec;123(12):1639-43
pubmed: 16344433
Eye (Lond). 2015 Aug;29(8):1027-35
pubmed: 26248525
Expert Rev Anticancer Ther. 2006 Apr;6(4):493-506
pubmed: 16613538
Transl Vis Sci Technol. 2021 Feb 5;10(2):24
pubmed: 34003909
J Natl Cancer Inst. 2021 Jan 4;113(1):80-87
pubmed: 32239153
Int J Oncol. 2020 Dec;57(6):1262-1279
pubmed: 33173970
Arch Ophthalmol. 1990 Sep;108(9):1268-73
pubmed: 2205183
Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1975 Mar-Apr;79(2):OP310-20
pubmed: 1145955
Cancer Control. 2004 Sep-Oct;11(5):304-9
pubmed: 15377989
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3335-3342
pubmed: 28672400
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
Br J Ophthalmol. 1978 Jun;62(6):420-5
pubmed: 352389
Br J Ophthalmol. 2023 Mar 9;:
pubmed: 36894300
Br J Cancer. 2022 Jun;126(11):1511-1528
pubmed: 35190695
Genes Dev. 2017 Apr 15;31(8):724-743
pubmed: 28512236
Ophthalmology. 1980 Jun;87(6):523-8
pubmed: 7413141
Prog Retin Eye Res. 2020 Mar;75:100800
pubmed: 31563544
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1405-11
pubmed: 16029800
Cancers (Basel). 2020 Jul 10;12(7):
pubmed: 32664236
Arch Ophthalmol. 2006 Jan;124(1):54-60
pubmed: 16401785
J Natl Compr Canc Netw. 2020 Feb;18(2):120-131
pubmed: 32023525
Radiother Oncol. 2012 Feb;102(2):219-24
pubmed: 21864922
J Clin Oncol. 2004 Jun 15;22(12):2438-44
pubmed: 15197206
Am J Ophthalmol. 2005 Oct;140(4):612-7
pubmed: 16226513
Cesk Slov Oftalmol. 2020 Winter;76(1):46-51
pubmed: 32917094
Eur J Ophthalmol. 2012 Mar-Apr;22(2):236-43
pubmed: 21959680
Arch Ophthalmol. 1985 Jul;103(7):924-31
pubmed: 4015483
Cancer Treat Rev. 2012 Aug;38(5):549-53
pubmed: 22270078
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):31
pubmed: 32186672
Br J Ophthalmol. 2005 Oct;89(10):1270-4
pubmed: 16170114
Ophthalmology. 2020 May;127(5):668-678
pubmed: 32081490
Retina. 2019 Oct;39(10):1840-1851
pubmed: 30608349
Int J Clin Exp Pathol. 2013 Jun 15;6(7):1230-44
pubmed: 23826405
Cancers (Basel). 2021 Nov 20;13(22):
pubmed: 34830987